Premium
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg TM CMA‐676)
Author(s) -
Petti Maria C.,
Pinazzi Maria B.,
Diverio Daniela,
Romano Atelda,
Petrucci Maria T.,
De Santis Silvia,
Meloni Giovanna,
Tafuri Agostino,
Mandelli Franco,
Lo Coco Francesco
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.03091.x
Subject(s) - gemtuzumab ozogamicin , medicine , calicheamicin , acute promyelocytic leukemia , chemotherapy , arsenic trioxide , salvage therapy , mitoxantrone , autologous stem cell transplantation , etoposide , oncology , gastroenterology , surgery , stem cell , retinoic acid , cd33 , myeloid leukemia , cd34 , chemistry , apoptosis , biochemistry , genetics , gene , biology
We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front‐line all‐ trans retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high‐dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.